aspirin has been researched along with Hypoxia in 73 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Hypoxia: Sub-optimal OXYGEN levels in the ambient air of living organisms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Based on the downregulation of CAIX level, both in vitro and in vivo, AcAs can overcome the acquired resistance and more effectively attenuate myocardial ischemia and hypoxia injury than that of aspirin." | 8.12 | An Original Aspirin-Containing Carbonic Anhydrase 9 Inhibitor Overcomes Hypoxia-Induced Drug Resistance to Enhance the Efficacy of Myocardial Protection. ( Fan, K; Gou, S; Liu, J; Yin, X; Zhang, B; Zhou, W, 2022) |
| "Since hypobaric hypoxia significantly affects metabolic characteristics of intestinal flora, which plays an important role in the biotransformation of aspirin, high altitudes may influence the pharmacokinetics and therapeutic effects of aspirin in the intestines." | 7.96 | Effects of intestinal flora on the pharmacokinetics and pharmacodynamics of aspirin in high-altitude hypoxia. ( Feng, Q; Li, W; Sun, Y; Wang, R; Zhang, J; Zhao, A, 2020) |
| "Aspirin use during pregnancy was associated with a reduced risk of hypoxia-related placental pathology in the high-risk population [the adjusted odds ratio and 95% confidence interval in the 1st, 2nd, and 3rd trimesters: 0." | 7.88 | Aspirin use during pregnancy and hypoxia-related placental pathology. ( Chen, C; Chen, Y; Feng, L; Ye, J; Ye, W; Zhang, J; Zhu, J; Zhu, X, 2018) |
| " Villous tissue was incubated at 2% O2 (hypoxia), 8% O2 and standard culture conditions (21% O2) or at 2% O2 and 21% O2 with dalteparin or ASA." | 7.80 | Hypoxia and the anticoagulants dalteparin and acetylsalicylic acid affect human placental amino acid transport. ( Darashchonak, N; Erlenwein, SV; Kleppa, MJ; von Kaisenberg, CS; von Versen-Höynck, F, 2014) |
| "To study the effect of aspirin on chronic hypoxia and hypercapnic pulmonary hypertension." | 7.72 | [Effect of aspirin on pulmonary hypertension in rat during chronic hypoxia and hypercapnia]. ( Chen, SX; Fan, XF; Wang, LX; Wang, MS; Zeng, HH, 2003) |
| "Self-reported use or consumption of tobacco, marijuana, cocaine, aspirin, and other nonsteroidal antiinflammatory drugs during pregnancy." | 7.69 | Persistent pulmonary hypertension of the newborn and smoking and aspirin and nonsteroidal antiinflammatory drug consumption during pregnancy. ( Allred, EN; Cohen, A; Epstein, MF; Leviton, A; Pagano, M; Sullivan, KF; Van Marter, LJ, 1996) |
| " In the present report we have provided experimental evidence that; (i) hypoxia of cardiac cells resulted in the production of adenosine (and its degradative products) which can be responsible for the hypoxic dilation observed by several workers; (ii) the release of metabolites such as potassium and inorganic phosphate was unchanged due to a 30-minute hypoxia of cardiac cells; (iii) the release of prostaglandin E but not F was enhanced due to hypoxia of cardiac cells which may be due to the storage pools in the cells; (iv) prostaglandin E1, E2 and F2 alpha inhibited the uptake of adenosine at pharmacological concentrations but not at physiological concentrations; (v) prostaglandin synthetase inhibitors (aspirin and indomethacin) nonspecifically inhibited the uptake of adenosine in the cardiac cells; (vi) lowering of pH resulted in inhibition in the uptake of adenosine and its incorporation into adenine nucleotides in cardiac cells; (vii) lowering the pH of the perfusion medium resulted in the increased release of perfusate adenosine (and its degradative products) with a simultaneous increase in coronary blood flow; (ix) specific adenosine receptor sites were found in cardiac muscle, coronary arteries, and carotid arteries of the dog and rabbit aorta, which satisfy the basic characteristic of receptor binding; and (x) these receptor binding sites were different from the adenosine uptake protein and were competitively blocked by theophylline or aminophylline." | 4.76 | Cellular and molecular mechanism(s) of coronary flow regulation by adenosine. ( Mustafa, SJ, 1980) |
| "Based on the downregulation of CAIX level, both in vitro and in vivo, AcAs can overcome the acquired resistance and more effectively attenuate myocardial ischemia and hypoxia injury than that of aspirin." | 4.12 | An Original Aspirin-Containing Carbonic Anhydrase 9 Inhibitor Overcomes Hypoxia-Induced Drug Resistance to Enhance the Efficacy of Myocardial Protection. ( Fan, K; Gou, S; Liu, J; Yin, X; Zhang, B; Zhou, W, 2022) |
| "Since hypobaric hypoxia significantly affects metabolic characteristics of intestinal flora, which plays an important role in the biotransformation of aspirin, high altitudes may influence the pharmacokinetics and therapeutic effects of aspirin in the intestines." | 3.96 | Effects of intestinal flora on the pharmacokinetics and pharmacodynamics of aspirin in high-altitude hypoxia. ( Feng, Q; Li, W; Sun, Y; Wang, R; Zhang, J; Zhao, A, 2020) |
| "Aspirin use during pregnancy was associated with a reduced risk of hypoxia-related placental pathology in the high-risk population [the adjusted odds ratio and 95% confidence interval in the 1st, 2nd, and 3rd trimesters: 0." | 3.88 | Aspirin use during pregnancy and hypoxia-related placental pathology. ( Chen, C; Chen, Y; Feng, L; Ye, J; Ye, W; Zhang, J; Zhu, J; Zhu, X, 2018) |
| " Villous tissue was incubated at 2% O2 (hypoxia), 8% O2 and standard culture conditions (21% O2) or at 2% O2 and 21% O2 with dalteparin or ASA." | 3.80 | Hypoxia and the anticoagulants dalteparin and acetylsalicylic acid affect human placental amino acid transport. ( Darashchonak, N; Erlenwein, SV; Kleppa, MJ; von Kaisenberg, CS; von Versen-Höynck, F, 2014) |
| "To study the effect of aspirin on chronic hypoxia and hypercapnic pulmonary hypertension." | 3.72 | [Effect of aspirin on pulmonary hypertension in rat during chronic hypoxia and hypercapnia]. ( Chen, SX; Fan, XF; Wang, LX; Wang, MS; Zeng, HH, 2003) |
| " In a mouse model of hypoxia-induced retinal angiogenesis, the situation of thrombocytopenia as well as inhibition of platelet aggregation by a highly specific alphaIIbbeta3-integrin antagonist or acetyl salicylic acid (Aspirin) administration, respectively, resulted in about 35-50% reduction of retinal neovascularization, compatible with a significant contribution of blood platelets in angiogenesis." | 3.72 | The functional role of blood platelet components in angiogenesis. ( Black, M; Fischer, S; Hammes, HP; Morgenstern, E; Preissner, KT; Rhee, JS; Schubert, U, 2004) |
| "Population spike amplitude (PSA) and NADH were measured during hypoxic hypoxia and recovery in hippocampal slices from untreated control animals (C slices) and slices prepared from animals pretreated in vivo with a single intraperitoneal injection of 3-nitropropionate (3NP) (3NP slices) or acetylsalicylate (ASA) (ASA slices)." | 3.70 | Primary hypoxic tolerance and chemical preconditioning during estrus cycle in mice. ( Huber, R; Kasischke, K; Li, H; Riepe, MW; Timmler, M, 1999) |
| "A cell culture model of bovine aortic endothelial cells attached to microcarrier beads was used to study the interaction of diaspirin cross-linked hemoglobin (an oxygen-carrying blood substitute) with hypoxia-reoxygenation." | 3.70 | Detection of a ferrylhemoglobin intermediate in an endothelial cell model after hypoxia-reoxygenation. ( Alayash, AI; McLeod, LL, 1999) |
| "Self-reported use or consumption of tobacco, marijuana, cocaine, aspirin, and other nonsteroidal antiinflammatory drugs during pregnancy." | 3.69 | Persistent pulmonary hypertension of the newborn and smoking and aspirin and nonsteroidal antiinflammatory drug consumption during pregnancy. ( Allred, EN; Cohen, A; Epstein, MF; Leviton, A; Pagano, M; Sullivan, KF; Van Marter, LJ, 1996) |
| " Aspirin, indomethacin, and ONO 3708, a PG receptor antagonist, markedly inhibited the hypoxia-induced contraction, whereas superoxide dismutase and OKY 046, a thromboxane (Tx) A2 synthesis inhibitor, were ineffective." | 3.68 | Comparison of hypoxia-induced contraction in human, monkey, and dog coronary arteries. ( Matsumoto, T; Toda, N; Yoshida, K, 1992) |
| "The effect of prostaglandin synthetase inhibitors, aspirin and indomethacin, salt overload and salt depletion, as well as renomedullary dissection on serum Ep level in rats exposed to acute hypoxia was studied." | 3.66 | Effects of prostaglandin synthetase inhibitors, salt overload and renomedullary dissection on the hypoxia stimulated erythropoietin production in rats. ( Biljanović-Paunović, L; Milenković, P; Pavlović-Kentera, V; Susić, D, 1980) |
| "In order to determine the role of prostaglandins in the regulation of pulmonary vascular resistance, we investigated effects of prostaglandin cyclo-oxygenase inhibition by indomethacin (2 mg/kg), meclofenamate (2 mg/kg), and aspirin (40 mg/kg) upon canine and feline pulmonary vasoconstriction caused by two stimuli: acute hypoxia (6% O2) and exogenous PGF2 alpha." | 3.66 | Contribution of prostaglandins to the regulation of pulmonary vascular resistance in adult cats and dogs. ( Leffler, CW; Passmore, JC, 1979) |
| " The inhibition of prostaglandin synthesis with indomethacin or aspirin blocks the vasodilatatory effect of hypercapnia and, to a lesser extent, of hypoxia." | 3.66 | [The metabolic regulation of the retinal blood flow and the role of prostaglandins (author's transl)]. ( Pournaras, C; Tsacopoulos, M, 1978) |
| "Both hypoxemia and a prothrombotic diathesis have been associated with more severe disease and increased risk of death." | 2.94 | Enhanced platelet inhibition treatment improves hypoxemia in patients with severe Covid-19 and hypercoagulability. A case control, proof of concept study. ( Forleo, GB; Radovanovic, D; Santus, P; Viecca, M, 2020) |
| "Having eliminated the common entity polycythemia vera, further direction for investigation is guided by the erythropoietin level." | 2.45 | Idiopathic erythrocytosis: a disappearing entity. ( McMullin, MF, 2009) |
| "Data are reviewed describing hypoxemia, a newly identified feature in thalassemia." | 2.38 | Hypoxemia in thalassemia. ( Bunyaratvej, A; Chantaraksri, U; Fucharoen, S; Piankijagum, A; Siritanaratkul, N; Sonakul, D; Wasi, P; Winichagoon, P, 1992) |
| "To determine the efficacy of a novel and safer (for gastrointestinal tract) aspirin (aspirin-PC) in preclinical models of ovarian cancer, in vitro dose-response studies were performed to compare the growth-inhibitory effect of aspirin-PC versus aspirin on three human (A2780, SKOV3ip1, and HeyA8) and a mouse (ID8) ovarian cancer cell line over an 8-day culture period." | 1.43 | Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer. ( Bottsford-Miller, JN; Dial, EJ; Dorniak, PL; Fang, D; Filant, J; Haemmerle, M; Hansen, JM; Hatakeyama, H; Hu, W; Huang, Y; Lichtenberger, LM; Lyons, Y; Pradeep, S; Previs, RA; Shen, F; Sood, AK; Taylor, M; Wagner, MJ, 2016) |
| "We sought to determine the prevalence of acute respiratory distress syndrome after intracerebral hemorrhage, characterize risk factors for its development, and assess its impact on patient outcomes." | 1.39 | Acute respiratory distress syndrome after spontaneous intracerebral hemorrhage*. ( Avery, L; Bajwa, E; Camargo, CA; Chang, Y; Duran-Mendicuti, MA; Elmer, J; Goldstein, JN; Greenberg, SM; Hess, DR; Hou, P; Okechukwu, I; Pallin, DJ; Pontes-Neto, O; Rosand, J; Schreiber, H; Wilcox, SR, 2013) |
| "Pretreatment with aspirin (10 mg/kg) protected the sheep against the pulmonary vascular response to 20 micrograms of PAF and blocked completely the thromboxane synthesis." | 1.27 | Effects of L-652,731, a platelet-activating factor (PAF) receptor antagonist, on PAF- and complement-induced pulmonary hypertension in sheep. ( McDonald, JW; Smallbone, BW; Taylor, NE, 1987) |
| "Prevention of arterial hypoxemia by oxygen breathing blocked an increase in pulmonary vascular resistance in four pretreated responders." | 1.26 | Failure of hypoxic pulmonary vasoconstriction in the canine asthma model. Effect of prostaglandin inhibitors. ( Baier, H; Cohn, MA; Wanner, A, 1978) |
| " The regime used was spironolactone in a dosage of 25 mg three times a day for two days preceding and during the periods spent at altitudes above 3,000 m." | 1.26 | Spironolactone and acute mountain sickness. ( Carter, PH; Champion, WL; Currie, TT; Fong, G; Francis, JK; McDonald, IH; Newing, RK; Nunn, IN; Sisson, RN; Sussex, M; Zacharin, RF, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 37 (50.68) | 18.7374 |
| 1990's | 15 (20.55) | 18.2507 |
| 2000's | 10 (13.70) | 29.6817 |
| 2010's | 8 (10.96) | 24.3611 |
| 2020's | 3 (4.11) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, Y | 1 |
| Zhang, J | 2 |
| Zhao, A | 1 |
| Li, W | 1 |
| Feng, Q | 1 |
| Wang, R | 1 |
| Viecca, M | 1 |
| Radovanovic, D | 1 |
| Forleo, GB | 1 |
| Santus, P | 1 |
| Zhou, W | 1 |
| Zhang, B | 1 |
| Fan, K | 1 |
| Yin, X | 1 |
| Liu, J | 1 |
| Gou, S | 1 |
| Gordon, RJ | 1 |
| Lombard, FW | 1 |
| Ye, J | 1 |
| Chen, Y | 1 |
| Zhu, J | 1 |
| Chen, C | 1 |
| Zhu, X | 1 |
| Feng, L | 1 |
| Ye, W | 1 |
| Elmer, J | 1 |
| Hou, P | 1 |
| Wilcox, SR | 1 |
| Chang, Y | 1 |
| Schreiber, H | 1 |
| Okechukwu, I | 1 |
| Pontes-Neto, O | 1 |
| Bajwa, E | 1 |
| Hess, DR | 1 |
| Avery, L | 1 |
| Duran-Mendicuti, MA | 1 |
| Camargo, CA | 1 |
| Greenberg, SM | 1 |
| Rosand, J | 1 |
| Pallin, DJ | 1 |
| Goldstein, JN | 1 |
| Kirkman, MA | 1 |
| Citerio, G | 1 |
| Smith, M | 1 |
| Kleppa, MJ | 1 |
| Erlenwein, SV | 1 |
| Darashchonak, N | 1 |
| von Kaisenberg, CS | 1 |
| von Versen-Höynck, F | 1 |
| Stub, D | 1 |
| Smith, K | 1 |
| Bernard, S | 1 |
| Nehme, Z | 1 |
| Stephenson, M | 1 |
| Bray, JE | 1 |
| Cameron, P | 1 |
| Barger, B | 1 |
| Ellims, AH | 1 |
| Taylor, AJ | 1 |
| Meredith, IT | 1 |
| Kaye, DM | 1 |
| Huang, Y | 1 |
| Lichtenberger, LM | 1 |
| Taylor, M | 1 |
| Bottsford-Miller, JN | 1 |
| Haemmerle, M | 1 |
| Wagner, MJ | 1 |
| Lyons, Y | 1 |
| Pradeep, S | 1 |
| Hu, W | 1 |
| Previs, RA | 1 |
| Hansen, JM | 1 |
| Fang, D | 1 |
| Dorniak, PL | 1 |
| Filant, J | 1 |
| Dial, EJ | 1 |
| Shen, F | 1 |
| Hatakeyama, H | 1 |
| Sood, AK | 1 |
| Kim, SW | 1 |
| Jeong, JY | 1 |
| Kim, HJ | 1 |
| Seo, JS | 1 |
| Han, PL | 1 |
| Yoon, SH | 1 |
| Lee, JK | 1 |
| McMullin, MF | 1 |
| Zeng, HH | 1 |
| Wang, LX | 1 |
| Chen, SX | 1 |
| Wang, MS | 1 |
| Fan, XF | 1 |
| LABRAM, C | 1 |
| SUBBA, PS | 1 |
| Weissmann, N | 4 |
| Akkayagil, E | 1 |
| Quanz, K | 2 |
| Schermuly, RT | 3 |
| Ghofrani, HA | 3 |
| Fink, L | 2 |
| Hänze, J | 1 |
| Rose, F | 1 |
| Seeger, W | 4 |
| Grimminger, F | 4 |
| González-Correa, JA | 1 |
| Arrebola, MM | 1 |
| Ureña, IM | 1 |
| Guerrero, A | 1 |
| Muñoz-Marín, J | 1 |
| Ruiz-Villafranca, D | 1 |
| Sánchez De La Cuesta, F | 1 |
| De La Cruz, JP | 1 |
| Rhee, JS | 1 |
| Black, M | 1 |
| Schubert, U | 1 |
| Fischer, S | 1 |
| Morgenstern, E | 1 |
| Hammes, HP | 1 |
| Preissner, KT | 1 |
| Manz, D | 1 |
| Buchspies, D | 1 |
| Keller, S | 1 |
| Mehling, T | 1 |
| Voswinckel, R | 2 |
| Gassmann, M | 1 |
| Pape, D | 1 |
| Linée, P | 1 |
| Lacroix, P | 1 |
| Allain, H | 1 |
| Reymann, JM | 1 |
| Le Pollès, JB | 1 |
| Van den Driessche, J | 1 |
| Knudsen, F | 1 |
| Nielsen, AH | 1 |
| Stoffersen, E | 1 |
| Kornerup, HJ | 1 |
| Dyerberg, J | 1 |
| Pavlović-Kentera, V | 3 |
| Susić, D | 3 |
| Biljanović-Paunović, L | 2 |
| Milenkoviĉ, P | 3 |
| Mustafa, SJ | 1 |
| Newman, PE | 1 |
| Fucharoen, S | 2 |
| Youngchaiyud, P | 1 |
| Wasi, P | 2 |
| Brimioulle, S | 3 |
| Lejeune, P | 3 |
| Vachiéry, JL | 2 |
| Delcroix, M | 3 |
| Hallemans, R | 3 |
| Leeman, M | 4 |
| Naeije, R | 5 |
| Van Marter, LJ | 1 |
| Leviton, A | 1 |
| Allred, EN | 1 |
| Pagano, M | 1 |
| Sullivan, KF | 1 |
| Cohen, A | 1 |
| Epstein, MF | 1 |
| Song, JY | 1 |
| Choi, JY | 1 |
| Ko, JT | 1 |
| Bae, EJ | 1 |
| Kim, HS | 1 |
| Noh, CI | 1 |
| Yoon, YS | 1 |
| Riepe, MW | 2 |
| Kasischke, K | 2 |
| Raupach, A | 1 |
| Conzen, J | 1 |
| Kiss, L | 1 |
| Jaffar, M | 1 |
| Everett, SA | 1 |
| Naylor, MA | 1 |
| Moore, SG | 1 |
| Ulhaq, S | 1 |
| Patel, KB | 1 |
| Stratford, MR | 1 |
| Nolan, J | 1 |
| Wardman, P | 1 |
| Stratford, IJ | 1 |
| Huber, R | 1 |
| Li, H | 1 |
| Timmler, M | 1 |
| McLeod, LL | 1 |
| Alayash, AI | 1 |
| Moro, MA | 1 |
| De Alba, J | 1 |
| Cárdenas, A | 1 |
| De Cristóbal, J | 1 |
| Leza, JC | 1 |
| Lizasoain, I | 1 |
| Díaz-Guerra, MJ | 1 |
| Boscá, L | 1 |
| Lorenzo, P | 1 |
| Tadic, A | 1 |
| Hardebusch, T | 1 |
| Hansen, J | 1 |
| Sander, M | 1 |
| Hald, CF | 1 |
| Victor, RG | 1 |
| Thomas, GD | 1 |
| Leffler, CW | 1 |
| Passmore, JC | 1 |
| Riley, DJ | 1 |
| Legawiec, BA | 1 |
| Santiago, TV | 1 |
| Edelman, NH | 1 |
| Pournaras, C | 2 |
| Tsacopoulos, M | 2 |
| Cohn, MA | 1 |
| Baier, H | 1 |
| Wanner, A | 1 |
| Hales, CA | 2 |
| Rouse, ET | 1 |
| Slate, JL | 1 |
| Chapuis, P | 1 |
| Rouse, E | 1 |
| Buchwald, IA | 1 |
| Kazemi, H | 1 |
| Alexander, JM | 1 |
| Nyby, MD | 1 |
| Jasberg, KA | 1 |
| Kalsner, S | 1 |
| Currie, TT | 1 |
| Carter, PH | 1 |
| Champion, WL | 1 |
| Fong, G | 1 |
| Francis, JK | 1 |
| McDonald, IH | 1 |
| Newing, RK | 1 |
| Nunn, IN | 1 |
| Sisson, RN | 1 |
| Sussex, M | 1 |
| Zacharin, RF | 1 |
| Coeugniet, E | 1 |
| Vaage, J | 2 |
| Hauge, A | 2 |
| Bjertnaes, L | 1 |
| Winichagoon, P | 1 |
| Siritanaratkul, N | 1 |
| Sonakul, D | 1 |
| Chantaraksri, U | 1 |
| Bunyaratvej, A | 1 |
| Piankijagum, A | 1 |
| Mózsik, G | 1 |
| Király, A | 1 |
| Sütö, G | 1 |
| Vincze, A | 1 |
| De Canniere, D | 1 |
| Stefanidis, C | 1 |
| Mélot, C | 3 |
| Toda, N | 1 |
| Matsumoto, T | 1 |
| Yoshida, K | 1 |
| Nolan, AM | 1 |
| Callingham, BA | 1 |
| Evans, RJ | 1 |
| Mazmanian, GM | 1 |
| Baudet, B | 1 |
| Brink, C | 1 |
| Cerrina, J | 1 |
| Kirkiacharian, S | 1 |
| Weiss, M | 1 |
| Smallbone, BW | 1 |
| Taylor, NE | 1 |
| McDonald, JW | 1 |
| Deloof, T | 1 |
| Wohns, RN | 1 |
| Said, SI | 2 |
| Yoshida, T | 2 |
| Kitamura, S | 1 |
| Vreim, C | 1 |
| Reeves, JT | 2 |
| Grover, RF | 2 |
| Bergentz, SE | 1 |
| Sutton, J | 1 |
| Lazarus, L | 1 |
| Appenzeller, O | 1 |
| Vaughan, DA | 1 |
| Korty, PR | 1 |
| Steele, JL | 1 |
| Okumura, H | 1 |
| Isoda, K | 1 |
| Aramaki, T | 1 |
| Ichikawa, T | 1 |
| Fukuda, N | 1 |
| Singh, I | 1 |
| Khanna, PK | 1 |
| Srivastava, MC | 1 |
| Lal, M | 1 |
| Roy, SB | 1 |
| Subramanyam, CS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Dynamics of Hemostatic Parameters in COVID-19 and Comparison of Intervention Strategies Through Adaptive Clinical Trial[NCT04466670] | Phase 2 | 379 participants (Anticipated) | Interventional | 2020-07-11 | Recruiting | ||
| A Randomised Controlled Trial of Oxygen Therapy in Acute Myocardial Infarction (AVOID - Air Verses Oxygen In myocarDial Infarction Study)[NCT01272713] | 638 participants (Actual) | Interventional | 2011-10-31 | Active, not recruiting | |||
| Strategy to Avoid Excessive Oxygen in Major Burn Patients (SAVE-O2)[NCT04534972] | Phase 3 | 2,000 participants (Anticipated) | Interventional | 2021-04-15 | Active, not recruiting | ||
| Strategy to Avoid Excessive Oxygen for Critically Ill Trauma Patients (SAVE-O2)[NCT04534959] | Phase 3 | 6,000 participants (Anticipated) | Interventional | 2020-10-15 | Active, not recruiting | ||
| DETermination of the Role of OXygen in Suspected Acute Myocardial Infarction (DETO2X-AMI) Based on the SWEDEHEART Registry[NCT01787110] | Phase 3 | 6,629 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)[NCT02409680] | 11,976 participants (Actual) | Interventional | 2016-03-23 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
- Early preterm delivery (<34 weeks) (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 189 |
| Placebo Arm | 230 |
- Birth weight <2500g (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 1078 |
| Placebo Arm | 1153 |
- Birth weight <1500g (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 78 |
| Placebo Arm | 101 |
- Incidence of Fetal Loss (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 303 |
| Placebo Arm | 353 |
- Incidence of Spontaneous Abortion (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 134 |
| Placebo Arm | 152 |
- Incidence of All stillbirth (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 141 |
| Placebo Arm | 166 |
- Incidence of Medical Termination of Pregnancy (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 42 |
| Placebo Arm | 30 |
- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy. (NCT02409680)
Timeframe: Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 352 |
| Placebo Arm | 325 |
- Incidence of Perinatal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 264 |
| Placebo Arm | 309 |
The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous. (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 668 |
| Placebo Arm | 754 |
- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 1506 |
| Placebo Arm | 1564 |
- Vaginal bleeding (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 214 |
| Placebo Arm | 246 |
- Antepartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 26 |
| Placebo Arm | 25 |
- Postpartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 54 |
| Placebo Arm | 43 |
- Incidence of Maternal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 9 |
| Placebo Arm | 12 |
- Incidence of Late Abortion (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 23 |
| Placebo Arm | 30 |
Hemoglobin < 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation (NCT02409680)
Timeframe: At enrollment, 4 weeks post enrollment, and 26-30 weeks GA.
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 290 |
| Placebo Arm | 333 |
Early preterm delivery (<34 weeks) and hypertensive disorders (i.e.: preeclampsia) (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 8 |
| Placebo Arm | 21 |
8 reviews available for aspirin and Hypoxia
| Article | Year |
|---|---|
Perioperative Venous Thromboembolism: A Review.
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductas | 2017 |
The intensive care management of acute ischemic stroke: an overview.
Topics: Airway Management; Anticoagulants; Aspirin; Decompressive Craniectomy; Endovascular Procedures; Fibr | 2014 |
Idiopathic erythrocytosis: a disappearing entity.
Topics: Adult; Aspirin; Blood Viscosity; Diagnosis, Differential; Erythropoiesis; Erythropoietin; Female; He | 2009 |
[Metabolic acidosis].
Topics: Acid-Base Equilibrium; Acidosis; Aspirin; Bicarbonates; Humans; Hydrogen-Ion Concentration; Hypoxia; | 2006 |
Cellular and molecular mechanism(s) of coronary flow regulation by adenosine.
Topics: Adenine Nucleotides; Adenosine; Animals; Aspirin; Carotid Arteries; Coronary Circulation; Coronary V | 1980 |
The coronary collateral circulation: determinants and functional significance in ischemic heart disease.
Topics: Adolescent; Animals; Arrhythmias, Cardiac; Arterial Occlusive Diseases; Aspirin; Blood Pressure; Col | 1981 |
Hypoxemia in thalassemia.
Topics: Aspirin; Blood Gas Analysis; Dipyridamole; Follow-Up Studies; Heart Failure; Humans; Hypoxia; Platel | 1992 |
Septic shock and disturbances in coagulation.
Topics: Acidosis; Acute Kidney Injury; Aminocaproates; Aspirin; Blood Coagulation Disorders; Blood Coagulati | 1974 |
4 trials available for aspirin and Hypoxia
| Article | Year |
|---|---|
Enhanced platelet inhibition treatment improves hypoxemia in patients with severe Covid-19 and hypercoagulability. A case control, proof of concept study.
Topics: Aged; Aspirin; Betacoronavirus; Clopidogrel; Compassionate Use Trials; Coronavirus Infections; COVID | 2020 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Air Versus Oxygen in ST-Segment-Elevation Myocardial Infarction.
Topics: Aged; Air; Ambulances; Aspirin; Biomarkers; Chest Pain; Combined Modality Therapy; Coronary Circulat | 2015 |
Metabolic modulation of sympathetic vasoconstriction in human skeletal muscle: role of tissue hypoxia.
Topics: Adult; Aspirin; Blood Pressure; Cyclooxygenase Inhibitors; Forearm; Hand Strength; Humans; Hypoxia; | 2000 |
Acute mountain sickness.
Topics: Acclimatization; Acute Disease; Adolescent; Adult; Altitude; Ammonium Chloride; Aspirin; Blood Flow | 1969 |
61 other studies available for aspirin and Hypoxia
| Article | Year |
|---|---|
Effects of intestinal flora on the pharmacokinetics and pharmacodynamics of aspirin in high-altitude hypoxia.
Topics: Altitude; Altitude Sickness; Animals; Aspirin; Feces; Gastrointestinal Microbiome; Hypoxia; Rats; Ra | 2020 |
An Original Aspirin-Containing Carbonic Anhydrase 9 Inhibitor Overcomes Hypoxia-Induced Drug Resistance to Enhance the Efficacy of Myocardial Protection.
Topics: Aspirin; Carbonic Anhydrase Inhibitors; Carbonic Anhydrase IX; Cell Line, Tumor; Drug Resistance; Hu | 2022 |
Aspirin use during pregnancy and hypoxia-related placental pathology.
Topics: Adult; Aspirin; Case-Control Studies; Female; Humans; Hypoxia; Middle Aged; Placenta; Placental Insu | 2018 |
Acute respiratory distress syndrome after spontaneous intracerebral hemorrhage*.
Topics: Acute Lung Injury; Aged; Aspirin; Cerebral Hemorrhage; Cohort Studies; Erythrocyte Transfusion; Fema | 2013 |
Hypoxia and the anticoagulants dalteparin and acetylsalicylic acid affect human placental amino acid transport.
Topics: Adaptor Proteins, Signal Transducing; Amino Acid Transport System A; Amino Acid Transport System L; | 2014 |
Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Aspirin; Biomarkers; Cell Line, | 2016 |
Combination treatment with ethyl pyruvate and aspirin enhances neuroprotection in the postischemic brain.
Topics: Animals; Aspirin; Astringents; Astrocytes; Brain Infarction; Cells, Cultured; Cerebral Cortex; Cytok | 2010 |
[Effect of aspirin on pulmonary hypertension in rat during chronic hypoxia and hypercapnia].
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Carotid Arteries; Epoprostenol; Hypercapnia; Hyperte | 2003 |
[THERAPEUTIC COMPLICATIONS OF ANALGESIC MEDICATIONS].
Topics: Agranulocytosis; Aminopyrine; Analgesics; Anemia; Anemia, Hemolytic; Aspirin; Drug Hypersensitivity; | 1964 |
CONTROL OF ACUTE MOUNTAIN SICKNESS.
Topics: Altitude Sickness; Anabolic Agents; Aspirin; Biomedical Research; Drug Therapy; Humans; Hypoxia; Met | 1964 |
Basic features of hypoxic pulmonary vasoconstriction in mice.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Amylopectin; Animals; Aspirin; B | 2004 |
Effects of triflusal on oxidative stress, prostaglandin production and nitric oxide pathway in a model of anoxia-reoxygenation in rat brain slices.
Topics: Analysis of Variance; Animals; Aspirin; Disease Models, Animal; Dose-Response Relationship, Drug; Gl | 2004 |
The functional role of blood platelet components in angiogenesis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Component Transfusion; Blood Platel | 2004 |
Congenital erythropoietin over-expression causes "anti-pulmonary hypertensive" structural and functional changes in mice, both in normoxia and hypoxia.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Aspirin; Blood Pressure | 2005 |
[Effect of ascorbic acid during acute iterative anoxia, hypothesis of an anti-oxidizing mechanism of action in comparison with the effect of hydroquinone].
Topics: Animals; Ascorbic Acid; Aspirin; Brain; Electroencephalography; Hydroquinones; Hypoxia; Lysine; Rats | 1980 |
Circulating platelet aggregates. A contributing factor to hemodialysis hypoxemia?
Topics: Aspirin; Humans; Hypoxia; Leukocyte Count; Platelet Aggregation; Platelet Count; Renal Dialysis | 1984 |
Prostaglandin synthesis inhibitors in erythropoiesis.
Topics: Animals; Aspirin; Bone Marrow; Bone Marrow Cells; Colony-Forming Units Assay; Erythropoiesis; Erythr | 1984 |
Effects of prostaglandin synthetase inhibitors, salt overload and renomedullary dissection on the hypoxia stimulated erythropoietin production in rats.
Topics: Acute Disease; Animals; Aspirin; Cyclooxygenase Inhibitors; Dissection; Erythropoietin; Hypoxia; Ind | 1980 |
Hypoxaemia and the effect of aspirin in thalassaemia.
Topics: Adolescent; Adult; Aspirin; Dipyridamole; Female; Humans; Hypoxia; Male; Middle Aged; Splenectomy; T | 1981 |
Stimulus-response curve of hypoxic pulmonary vasoconstriction in intact dogs: effects of ASA.
Topics: Acid-Base Equilibrium; Acidosis; Animals; Aspirin; Blood Gas Analysis; Cardiac Output; Cyclooxygenas | 1994 |
Persistent pulmonary hypertension of the newborn and smoking and aspirin and nonsteroidal antiinflammatory drug consumption during pregnancy.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Cocaine; Confounding | 1996 |
Long-term aspirin therapy for hepatopulmonary syndrome.
Topics: Aspirin; Child; Chronic Disease; Cyanosis; Dilatation, Pathologic; Female; Humans; Hypoxia; Liver Di | 1996 |
Acetylsalicylic acid increases tolerance against hypoxic and chemical hypoxia.
Topics: Action Potentials; Adaptation, Physiological; Adenosine Triphosphate; Animals; Aspirin; Extracellula | 1997 |
Effects of arachidonic acid metabolism on hypoxic vasoconstriction in rabbit lungs.
Topics: 4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine; Animals; Arachidonic Acid; Aspirin; Cy | 1998 |
Prodrugs for targeting hypoxic tissues: regiospecific elimination of aspirin from reduced indolequinones.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Free Radicals; Humans; Hypoxia | 1999 |
Primary hypoxic tolerance and chemical preconditioning during estrus cycle in mice.
Topics: Action Potentials; Adaptation, Physiological; Animals; Aspirin; Dose-Response Relationship, Drug; Es | 1999 |
Detection of a ferrylhemoglobin intermediate in an endothelial cell model after hypoxia-reoxygenation.
Topics: Animals; Aspirin; Cattle; Cells, Cultured; Endothelium, Vascular; Hemoglobin A; Hemoglobins; Hydroge | 1999 |
Mechanisms of the neuroprotective effect of aspirin after oxygen and glucose deprivation in rat forebrain slices.
Topics: Animals; Aspirin; Blotting, Western; Cell Nucleus; Chromatography, High Pressure Liquid; Cytosol; El | 2000 |
Nitric oxide (NO)-dependent but not NO-independent guanylate cyclase activation attenuates hypoxic vasoconstriction in rabbit lungs.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Aminoquinolines; Animals; Aspiri | 2000 |
Contribution of prostaglandins to the regulation of pulmonary vascular resistance in adult cats and dogs.
Topics: Animals; Arachidonic Acids; Aspirin; Cats; Cyclooxygenase Inhibitors; Dogs; Hypoxia; Indomethacin; M | 1979 |
The effect of aspirin on erythropoietin formation in the rat.
Topics: Animals; Aspirin; Erythropoietin; Hydronephrosis; Hypoxia; Kidney; Male; Prostaglandins; Rats | 1979 |
Ventilatory responses to hypercapnia and hypoxia during continuous aspirin ingestion.
Topics: Adult; Aspirin; Bicarbonates; Female; Humans; Hypercapnia; Hypoxia; Male; Oxygen Consumption; Respir | 1977 |
[The metabolic regulation of the retinal blood flow and the role of prostaglandins (author's transl)].
Topics: Animals; Arterioles; Aspirin; Histamine; Hypercapnia; Hypoxia; Indomethacin; Prostaglandins E; Regio | 1978 |
Failure of hypoxic pulmonary vasoconstriction in the canine asthma model. Effect of prostaglandin inhibitors.
Topics: Animals; Ascaris; Aspirin; Asthma; Dogs; Hypersensitivity; Hypoxia; Indomethacin; Lung; Oxygen; Pros | 1978 |
Influence of aspirin and indomethacin on variability of alveolar hypoxic vasoconstriction.
Topics: Animals; Aspirin; Dogs; Hypoxia; In Vitro Techniques; Indomethacin; Nitrogen; Oxygen; Pulmonary Alve | 1978 |
Studies on the role of prostaglandins in the regulation of retinal blood flow.
Topics: Animals; Arterioles; Aspirin; Fluorescein Angiography; Hypercapnia; Hypoxia; Indomethacin; Prostagla | 1978 |
Role of prostaglandins in alveolar hypoxic vasoconstriction.
Topics: Animals; Aspirin; Blood Gas Analysis; Blood Pressure; Dogs; Dose-Response Relationship, Drug; Hypoxi | 1977 |
Prostaglandin synthesis inhibition restores hypoxic pulmonary vasoconstriction.
Topics: Animals; Aspirin; Blood Pressure; Dogs; Hypoxia; Indomethacin; Prostaglandins; Pulmonary Artery; Pul | 1977 |
Intrinsic prostaglandin release. A mediator of anoxia-induced relaxation in an isolated coronary artery preparation.
Topics: 5,8,11,14-Eicosatetraynoic Acid; Animals; Arteries; Aspirin; Cattle; Coronary Vessels; Hypoxia; Indo | 1976 |
Spironolactone and acute mountain sickness.
Topics: Acute Disease; Adult; Altitude Sickness; Aspirin; Female; Furosemide; Humans; Hypoxia; Male; Middle | 1976 |
Drugs with antithrombotic effect: experimental study.
Topics: Animals; Aspirin; Dipyridamole; Drug Synergism; Heparin; Hypoxia; Lysine; Mice; Platelet Aggregation | 1976 |
Letter: Prostaglandins and the pulmonary vasoconstrictor response to alveolar hypoxia.
Topics: Animals; Aspirin; Biological Assay; Blood Pressure; Cats; Hypoxia; In Vitro Techniques; Muscle, Smoo | 1975 |
The pulmonary vasoconstrictor response to hypoxia: effects of inhibitors of prostaglandin biosynthesis.
Topics: Animals; Aspirin; Blood Pressure; Depression, Chemical; Hypoxia; Indomethacin; Meclofenamic Acid; or | 1975 |
ATP breakdown and resynthesis in the development of gastrointestinal mucosal damage and its prevention in animals and human (an overview of 25 years ulcer research studies).
Topics: Adenosine Triphosphate; Animals; Aspirin; Atropine; Capillary Permeability; Female; Food; Gastric Mu | 1992 |
Stimulus-response curves for hypoxic pulmonary vasoconstriction in piglets.
Topics: Animals; Aspirin; Blood Pressure; Doxapram; Hypoxia; Pulmonary Artery; Stimulation, Chemical; Swine; | 1992 |
Blunted hypoxic vasoconstriction in oleic acid lung injury: effect of cyclooxygenase inhibitors.
Topics: Animals; Aspirin; Cyclooxygenase Inhibitors; Dogs; Epoprostenol; Hypoxia; Indomethacin; Lung; Lung I | 1992 |
Comparison of hypoxia-induced contraction in human, monkey, and dog coronary arteries.
Topics: Animals; Aspirin; Coronary Vessels; Dinoprost; Dogs; Endothelium, Vascular; Female; Humans; Hypoxia; | 1992 |
Enhancement of hypoxic pulmonary vasoconstriction by metabolic acidosis in dogs.
Topics: Acidosis; Animals; Aspirin; Bicarbonates; Blood Pressure; Carbon Dioxide; Cardiac Output; Dogs; Hear | 1990 |
Effects of aspirin on xylazine-induced hypoxaemia in sheep.
Topics: Animals; Aspirin; Female; Hypoxia; Injections, Intravenous; Male; Oxygen; Platelet Aggregation; Plat | 1990 |
Methylene blue potentiates vascular reactivity in isolated rat lungs.
Topics: Angiotensin II; Animals; Aspirin; Hemoglobins; Hypoxia; Lung; Male; Methylene Blue; Pulmonary Circul | 1989 |
Effects of L-652,731, a platelet-activating factor (PAF) receptor antagonist, on PAF- and complement-induced pulmonary hypertension in sheep.
Topics: Animals; Aspirin; Complement Activation; Complement System Proteins; Dose-Response Relationship, Dru | 1987 |
Multipoint pulmonary vascular pressure/flow relationships in hypoxic and in normoxic dogs: effects of nitrous oxide with and without cyclooxygenase inhibition.
Topics: Animals; Aspirin; Blood Pressure; Cyclooxygenase Inhibitors; Dogs; Hypoxia; Nitrous Oxide; Pulmonary | 1988 |
Transient ischemic attacks at high altitude.
Topics: Adult; Altitude Sickness; Aspirin; Fluid Therapy; Humans; Hypoxia; Ischemic Attack, Transient; Male; | 1986 |
Pulmonary alveolar hypoxia: release of prostaglandins and other humoral mediators.
Topics: Animals; Aspirin; Biological Assay; Blood Pressure; Cats; Depression, Chemical; Hypoxia; Muscle Cont | 1974 |
Blockade of acute hypoxic pulmonary hypertension by endotoxin.
Topics: Animals; Aspirin; Blood Pressure; Cardiac Output; Dogs; Endotoxins; Escherichia coli; Hypertension, | 1974 |
Loss of hypoxic pulmonary vasoconstriction in dogs given small amounts of endotoxin.
Topics: Animals; Aspirin; Blood Pressure; Dogs; Endotoxins; Escherichia coli; Hypoxia; Pulmonary Artery; Pul | 1974 |
Mountain sickness in the Australian alps.
Topics: Adolescent; Adult; Aged; Altitude; Aspirin; Australia; Child; Female; Humans; Hypoxia; Male; Menstru | 1973 |
Release of prostaglandins and other humoral mediators during hypoxic breathing and pulmonary edema.
Topics: Acetylcholine; Animals; Aspirin; Catecholamines; Cats; Colon; Dextrans; Gallbladder; Guinea Pigs; Hi | 1974 |
Altitude headache.
Topics: Acetazolamide; Altitude; Ammonium Chloride; Aspirin; Furosemide; Headache; Humans; Hypoxia; Potassiu | 1972 |
Effects of hypoxia and dietary aspirin on plasma and urinary amino acids in the rat.
Topics: Altitude; Amino Acids; Animals; Aspirin; Diet; Hypoxia; Male; Rats | 1969 |
[Aspirin esterase activity test as a new liver function test].
Topics: Animals; Aspirin; Clinical Enzyme Tests; Esterases; Heart Failure; Hepatitis; Humans; Hypoxia; Liver | 1971 |